title: [The role of radical prostatectomy in cT3 prostate carcinoma].
abstract: A clinical cT3 prostate cancer can mean so many different tumors, that no single approach can actually be proposed. Radical prostatectomy has become standard treatment for T1/T2 tumors, but the surgical treatment for the clinical T3 prostate cancer has always been and remains controversial, although some urologists felt that radical prostatectomy remained a treatment option for T3 prostatic cancer when poor prognosis patients were excluded. The clinical staging of locally confined or locally advanced prostate cancer is not reliable. More than 70% of the clinically T2-tumors are pT3. On the others hand clinically T3-tumors are sometimes overestimated and about 20% of the clinical T3 cancers were shown to be pT2.--At the Department of Urology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium--158 patients had radical prostatectomy for clinical stage T3N0M0 prostate cancer. 110 patients were surgically treated only. 30 patients had adjuvant hormone-therapy and were considered to be progressive at 1 month because PSA follow-up is unreliable. 18 other patients were irradiated postoperatively. PSA-free survival rate exceeds 70% at 24 months and the 5 years estimated PSA-free survival is more than 60%. Summarizing radical prostatectomy appears to be a justified treatment modality in pT3-prostate cancer, if PSA is < 10 ng/ml.
authors.affiliation: Departement of Urology, Katholieke Universiteit Leuven, Belgium.
authors.forename: H
authors.initials: H
authors.lastname: Van Poppel
authors.forename: H
authors.initials: H
authors.lastname: Goethuys
authors.forename: P
authors.initials: P
authors.lastname: Callewaert
authors.forename: L
authors.initials: L
authors.lastname: Vanuytsel
authors.forename: W
authors.initials: W
authors.lastname: Van de Voorde
authors.forename: L
authors.initials: L
authors.lastname: Baert
mesh_terms: D000368:Aged; D001530:Belgium; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen